Integrating oncolytic viruses in combination cancer immunotherapy (original) (raw)

• Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014–1022 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010). This is a randomized clinical trial demonstrating a clinical benefit of ipilimumab, the first immune checkpoint inhibitor that was approved for the treatment of melanoma.
  Article PubMed PubMed Central CAS Google Scholar
• Grosso, J. F. & Jure-Kunkel, M. N. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 13, 5 (2013).
  PubMed PubMed Central Google Scholar
• Sehgal, A., Whiteside, T. L. & Boyiadzis, M. Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opin. Biol. Ther. 15, 1191–1203 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Michot, J. M. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139–148 (2016).
  Article PubMed CAS Google Scholar
• Andrews, A. Treating with checkpoint inhibitors — figure $1 million per patient. Am. Health Drug Benefits 8, 9 (2015).
  PubMed PubMed Central Google Scholar
• Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Teng, M. W., Ngiow, S. F., Ribas, A. & Smyth, M. J. Classifying cancers based on T cell infiltration and PD-L1. Cancer Res. 75, 2139–2145 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275–287 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017). This is an excellent review article describing the cancer–immunity cycle and the three different immunological tumour phenotypes.
  Article PubMed CAS Google Scholar
• Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017). This study investigates baseline gene expression signatures in patients who respond to PD1 therapy and establishes a T cell-inflamed gene expression signature as a predictive biomarker.
  Article PubMed PubMed Central Google Scholar
• Prat, A. et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 77, 3540–3550 (2017).
  Article PubMed CAS Google Scholar
• Charoentong, P. et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18, 248–262 (2017).
  Article PubMed CAS Google Scholar
• Bommareddy, P. K., Patel, A., Hossain, S. & Kaufman, H. L. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am. J. Clin. Dermatol. 18, 1–15 (2017).
  Article PubMed Google Scholar
• Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642–662 (2015). This is a comprehensive review of oncolytic viruses in clinical development and of key considerations in drug development using oncolytic virus platforms.
  Article PubMed CAS Google Scholar
• Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl Med. 6, 226ra32 (2014). This is one of the first research articles to report preclinical data demonstrating improved therapeutic responses using combination therapy with an oncolytic virus and an immune checkpoint inhibitor.
  Article PubMed PubMed Central CAS Google Scholar
• Thomann, S. et al. Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells. Immunology 146, 327–338 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Mogensen, T. H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22, 240–273 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Bommareddy, P. K., Silk, A. W. & Kaufman, H. L. Intratumoral approaches for the treatment of melanoma. Cancer J. 23, 40–47 (2017).
  Article PubMed Google Scholar
• Larocca, C. & Schlom, J. Viral vector-based therapeutic cancer vaccines. Cancer J. 17, 359–371 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Harrop, R. & Carroll, M. W. Viral vectors for cancer immunotherapy. Front. Biosci. 11, 804–817 (2006).
  Article PubMed CAS Google Scholar
• Haseley, A., Alvarez-Breckenridge, C., Chaudhury, A. R. & Kaur, B. Advances in oncolytic virus therapy for glioma. Recent Pat. CNS Drug Discov. 4, 1–13 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Fernandes, J. Oncogenes: the passport for viral oncolysis through PKR inhibition. Biomark Cancer 8, 101–110 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Mounir, Z. et al. Tumor suppression by PTEN requires the activation of the PKR-eIF2α phosphorylation pathway. Sci. Signal. 2, ra85 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Marsh, M. & Helenius, A. Virus entry: open sesame. Cell 124, 729–740 (2006).
  Article PubMed CAS Google Scholar
• Bommareddy, P. K. & Kaufman, H. L. Unleashing the therapeutic potential of oncolytic viruses. J. Clin. Invest. 128, 1258–1260 (2018).
  Article PubMed Google Scholar
• Tuve, S. et al. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J. Virol. 80, 12109–12120 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Uchida, H. et al. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol. Ther. 21, 561–569 (2013).
  Article PubMed CAS Google Scholar
• Xia, T., Konno, H. & Barber, G. N. Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis. Cancer Res. 76, 6747–6759 (2016).
  Article PubMed CAS Google Scholar
• Xia, T., Konno, H., Ahn, J. & Barber, G. N. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep. 14, 282–297 (2016).
  Article PubMed CAS Google Scholar
• Vile, R. G. & Hart, I. R. Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences. Ann. Oncol. 5(Suppl. 4), 59–65 (1994).
  Article PubMed Google Scholar
• Pelka, P. et al. Adenovirus E1A directly targets the E2F/DP-1 complex. J. Virol. 85, 8841–8851 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Savontaus, M. J., Sauter, B. V., Huang, T. G. & Woo, S. L. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther. 9, 972–979 (2002).
  Article PubMed CAS Google Scholar
• Cassady, K. A. & Gross, M. The herpes simplex virus type 1 U(S)11 protein interacts with protein kinase R in infected cells and requires a 30-amino-acid sequence adjacent to a kinase substrate domain. J. Virol. 76, 2029–2035 (2002).
  Article PubMed PubMed Central CAS Google Scholar
• Liu, B. L. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10, 292–303 (2003). This is the original paper describing that ICP34.5-deleted HSV-1 encoding GM-CSF has therapeutic activity in preclinical tumour models.
  Article PubMed CAS Google Scholar
• Deng, L. et al. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9. Oncotarget 8, 40533–40543 (2017).
  PubMed PubMed Central Google Scholar
• Zinn, R. L., Pruitt, K., Eguchi, S., Baylin, S. B. & Herman, J. G. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res. 67, 194–201 (2007).
  Article PubMed CAS Google Scholar
• Potts, K. G., Hitt, M. M. & Moore, R. B. Oncolytic viruses in the treatment of bladder cancer. Adv. Urol. 2012, 404581 (2012).
  Article PubMed PubMed Central Google Scholar
• Chung, R. Y., Saeki, Y. & Chiocca, E. A. B-Myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J. Virol. 73, 7556–7564 (1999).
  PubMed PubMed Central CAS Google Scholar
• Singh, P. K., Doley, J., Kumar, G. R., Sahoo, A. P. & Tiwari, A. K. Oncolytic viruses and their specific targeting to tumour cells. Indian J. Med. Res. 136, 571–584 (2012).
  PubMed PubMed Central Google Scholar
• Hu, J. C. et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 12, 6737–6747 (2006).
  Article PubMed CAS Google Scholar
• Garg, A. D., Dudek-Peric, A. M., Romano, E. & Agostinis, P. Immunogenic cell death. Int. J. Dev. Biol. 59, 131–140 (2015).
  Article PubMed CAS Google Scholar
• Kepp, O. et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3, e955691 (2014).
  Article PubMed PubMed Central Google Scholar
• Haag, F. et al. Extracellular NAD and ATP: Partners in immune cell modulation. Purinerg. Signal. 3, 71–81 (2007).
  Article CAS Google Scholar
• Gardai, S. J. et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through _trans_-activation of LRP on the phagocyte. Cell 123, 321–334 (2005).
  Article PubMed CAS Google Scholar
• Bracci, L., Schiavoni, G., Sistigu, A. & Belardelli, F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21, 15–25 (2014).
  Article PubMed CAS Google Scholar
• Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711–723.e4 (2017). This study investigates a potential link between the presence of BATF3-driven DCs within the tumour microenvironment and the recruitment of effector T cells.
  Article PubMed PubMed Central CAS Google Scholar
• Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8α+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097–1100 (2008). This study shows that deletion of the transcription factor BATF3 inhibits the development of CD8α+ DCs and that cross-presentation by these cells mediates antiviral and antitumour immunity.
  Article PubMed PubMed Central CAS Google Scholar
• Brendan Horton, L. S. S. The non-T cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions. Emerg. Top. Life Sci. 5, 447–456 (2017).
  Article Google Scholar
• Dai, P. et al. Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Sci. Immunol. 2, eaal1713 (2017).
  Article PubMed PubMed Central Google Scholar
• Schmidt, S. V., Nino-Castro, A. C. & Schultze, J. L. Regulatory dendritic cells: there is more than just immune activation. Front. Immunol. 3, 274 (2012).
  PubMed PubMed Central Google Scholar
• Kell, A. M. & Gale, M. Jr. RIG-I in RNA virus recognition. Virology 479–480, 110–121 (2015).
  Article PubMed CAS Google Scholar
• Cai, X., Chiu, Y. H. & Chen, Z. J. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol. Cell 54, 289–296 (2014).
  Article PubMed CAS Google Scholar
• Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830–842 (2014). This study demonstrates that the host STING pathway is a major mechanism of innate sensing of cancers.
  Article PubMed PubMed Central CAS Google Scholar
• Mihret, A., Mamo, G., Tafesse, M., Hailu, A. & Parida, S. Dendritic cells activate and mature after infection with Mycobacterium tuberculosis. BMC Res. Notes 4, 247 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805–820 (2010).
  Article PubMed CAS Google Scholar
• Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Wakimoto, H., Johnson, P. R., Knipe, D. M. & Chiocca, E. A. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. 10, 983–990 (2003).
  Article PubMed CAS Google Scholar
• Saha, D., Wakimoto, H. & Rabkin, S. D. Oncolytic herpes simplex virus interactions with the host immune system. Curr. Opin. Virol. 21, 26–34 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Zamarin, D. et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J. Clin. Invest. 128, 1413–1428 (2018).
  Article PubMed PubMed Central Google Scholar
• Uehara, J. et al. Intratumoral injection of IFN-beta induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb. Biochem. Biophys. Res. Commun. 490, 521–527 (2017).
  Article PubMed CAS Google Scholar
• Cheng, X. et al. The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma. J. Neuroimmunol. 185, 75–86 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• DiPaola, R. S. et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J. Transl Med. 4, 1 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Zamarin, D. & Wolchok, J. D. Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Mol. Ther. Oncolyt. 1, 14004 (2014).
  Article CAS Google Scholar
• Grekova, S. et al. Activation of an antiviral response in normal but not transformed mouse cells: a new determinant of minute virus of mice oncotropism. J. Virol. 84, 516–531 (2010).
  Article PubMed CAS Google Scholar
• Joffre, O. P., Segura, E., Savina, A. & Amigorena, S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12, 557–569 (2012).
  Article PubMed CAS Google Scholar
• Muller, M., Carter, S., Hofer, M. J. & Campbell, I. L. Review: the chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity — a tale of conflict and conundrum. Neuropathol. Appl. Neurobiol. 36, 368–387 (2010).
  Article PubMed CAS Google Scholar
• Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M. & van Hall, T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr. Opin. Immunol. 39, 44–51 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Verweij, M. C. et al. Viral inhibition of the transporter associated with antigen processing (TAP): a striking example of functional convergent evolution. PLoS Pathog. 11, e1004743 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Goldsmith, K., Chen, W., Johnson, D. C. & Hendricks, R. L. Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response. J. Exp. Med. 187, 341–348 (1998).
  Article PubMed PubMed Central CAS Google Scholar
• Brode, S. & Macary, P. A. Cross-presentation: dendritic cells and macrophages bite off more than they can chew! Immunology 112, 345–351 (2004).
  Article PubMed PubMed Central CAS Google Scholar
• Nesslinger, N. J. et al. A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin. Cancer Res. 16, 4046–4056 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Russell, S. J. & Peng, K. W. Oncolytic virotherapy: a contest between apples and oranges. Mol. Ther. 25, 1107–1116 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Gulley, J. L. et al. Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J. Natl Cancer Inst. 109, djw261 (2017).
  Article PubMed Central Google Scholar
• Woller, N. et al. Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T cell responses. Mol. Ther. 23, 1630–1640 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Smith-Garvin, J. E., Koretzky, G. A. & Jordan, M. S. T cell activation. Annu. Rev. Immunol. 27, 591–619 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Curtsinger, J. M. & Mescher, M. F. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 22, 333–340 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Lapteva, N. et al. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol. Ther. 17, 1626–1636 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Gujar, S. A. & Lee, P. W. Oncolytic virus-mediated reversal of impaired tumor antigen presentation. Front. Oncol. 4, 77 (2014).
  Article PubMed PubMed Central Google Scholar
• Gujar, S. et al. Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. Mol. Ther. 21, 338–347 (2013).
  Article PubMed CAS Google Scholar
• Zamarin, D. et al. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat. Commun. 8, 14340 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Barber, G. N. Host defense, viruses and apoptosis. Cell Death Differ. 8, 113–126 (2001).
  Article PubMed CAS Google Scholar
• Petersen, J. L., Morris, C. R. & Solheim, J. C. Virus evasion of MHC class I molecule presentation. J. Immunol. 171, 4473–4478 (2003).
  Article PubMed CAS Google Scholar
• Su, X. et al. TNF receptor-associated factor-1 (TRAF1) negatively regulates Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF)-mediated signaling. Eur. J. Immunol. 36, 199–206 (2006).
  Article PubMed CAS Google Scholar
• Dorner, T. & Radbruch, A. Antibodies and B cell memory in viral immunity. Immunity 27, 384–392 (2007).
  Article PubMed CAS Google Scholar
• Ferguson, M. S., Lemoine, N. R. & Wang, Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv. Virol. 2012, 805629 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Bhattacharya, P. et al. Dual role of GM-CSF as a pro-inflammatory and a regulatory cytokine: implications for immune therapy. J. Interferon Cytokine Res. 35, 585–599 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Tahtinen, S. et al. T-cell therapy enabling adenoviruses coding for IL2 and TNFα induce systemic immunomodulation in mice with spontaneous melanoma. J. Immunother. 39, 343–354 (2016).
  Article PubMed CAS Google Scholar
• Passer, B. J. et al. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Cancer Gene Ther. 20, 17–24 (2013).
  Article PubMed CAS Google Scholar
• Uchida, H. et al. Oncolytic herpes simplex virus vectors fully retargeted to tumor- associated antigens. Curr. Cancer Drug Targets 18, 162–170 (2018).
  Article PubMed CAS Google Scholar
• Choi, J. W., Lee, Y. S., Yun, C. O. & Kim, S. W. Polymeric oncolytic adenovirus for cancer gene therapy. J. Control. Release 219, 181–191 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Wang, J., Lu, X. X., Chen, D. Z., Li, S. F. & Zhang, L. S. Herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer. World J. Gastroenterol. 10, 400–403 (2004).
  Article PubMed PubMed Central CAS Google Scholar
• Li, J. M. et al. MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells. Virol. J. 10, 241 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Ruiz, A. J. & Russell, S. J. MicroRNAs and oncolytic viruses. Curr. Opin. Virol. 13, 40–48 (2015).
  Article PubMed CAS Google Scholar
• Breitbach, C. J. et al. Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 19, 886–894 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Eichmann, A. & Simons, M. VEGF signaling inside vascular endothelial cells and beyond. Curr. Opin. Cell Biol. 24, 188–193 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Arulanandam, R. et al. VEGF-mediated induction of PRD1-BF1/Blimp1 expression sensitizes tumor vasculature to oncolytic virus infection. Cancer Cell 28, 210–224 (2015).
  Article PubMed CAS Google Scholar
• Critchley-Thorne, R. J. et al. Impaired interferon signaling is a common immune defect in human cancer. Proc. Natl Acad. Sci. USA 106, 9010–9015 (2009). This study demonstrates that interferon response genes are dysregulated in cancer cells.
  Article PubMed Google Scholar
• Eriksson, E. et al. Activation of myeloid and endothelial cells by CD40L gene therapy supports T cell expansion and migration into the tumor microenvironment. Gene Ther. 24, 92–103 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780–2788 (2015). This randomized clinical trial demonstrated a therapeutic benefit of treating patients with advanced melanoma with oncolytic HSV encoding GM-CSF; these data led to regulatory approval of this treatment in the USA, Europe and Australia.
  Article PubMed CAS Google Scholar
• Cheng, P. H., Wechman, S. L., McMasters, K. M. & Zhou, H. S. Oncolytic replication of E1b-deleted adenoviruses. Viruses 7, 5767–5779 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Khuri, F. R. et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879–885 (2000).
  Article PubMed CAS Google Scholar
• John, J. et al. Differential effects of Paclitaxel on dendritic cell function. BMC Immunol. 11, 14 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Pfirschke, C. et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44, 343–354 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Roulstone, V. et al. BRAF- and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress. Mol. Ther. 23, 931–942 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Gholami, S. et al. Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. Cancer Gene Ther. 21, 283–289 (2014).
  Article PubMed CAS Google Scholar
• Diana, A. et al. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 7, 40992–41004 (2016).
  PubMed PubMed Central Google Scholar
• Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064–5074 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Liu, Z., Ravindranathan, R., Kalinski, P., Guo, Z. S. & Bartlett, D. L. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat. Commun. 8, 14754 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Intlekofer, A. M. & Thompson, C. B. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol. 94, 25–39 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Bourgeois-Daigneault, M. C. et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci. Transl Med. 10, eaao1641 (2018).
  Article PubMed Google Scholar
• Kleinpeter, P. et al. Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. Oncoimmunology 5, e1220467 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Ilett, E. et al. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. Gene Ther. 24, 21–30 (2017).
  Article PubMed CAS Google Scholar
• Puzanov, I. et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J. Clin. Oncol. 34, 2619–2626 (2016).
  Article PubMed CAS Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02263508 (2018).
• Silk, A. W. et al. Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial [abstract]. Cancer Res. 77 (Suppl), CT026 (2017).
  Article Google Scholar
• Lichty, B. D., Breitbach, C. J., Stojdl, D. F. & Bell, J. C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 14, 559 (2014).
  Article PubMed CAS Google Scholar
• Ajina, A. & Maher, J. Prospects for combined use of oncolytic viruses and CAR T-cells. J. Immunother. Cancer 5, 90 (2017).
  Article PubMed PubMed Central Google Scholar
• Nishio, N. & Dotti, G. Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors. Oncoimmunology 4, e988098 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Sharabi, A. B., Lim, M., DeWeese, T. L. & Drake, C. G. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 16, e498–509 (2015).
  Article PubMed Google Scholar
• Kang, J., Demaria, S. & Formenti, S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J. Immunother. Cancer 4, 51 (2016).
  Article PubMed PubMed Central Google Scholar
• Ottolino-Perry, K., Diallo, J. S., Lichty, B. D., Bell, J. C. & McCart, J. A. Intelligent design: combination therapy with oncolytic viruses. Mol. Ther. 18, 251–263 (2010).
  Article PubMed CAS Google Scholar
• O’Cathail, S. M. et al. Combining oncolytic adenovirus with radiation — a paradigm for the future of radiosensitization. Front. Oncol. 7, 153 (2017).
  Article PubMed PubMed Central Google Scholar
• Kanai, R. et al. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J. Natl Cancer Inst. 104, 42–55 (2012).
  Article PubMed CAS Google Scholar
• Adusumilli, P. S. et al. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. Ann. Thorac Surg. 80, 409–416 (2005).
  Article PubMed PubMed Central Google Scholar
• Harrington, K. J. et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res. 16, 4005–4015 (2010).
  Article PubMed CAS Google Scholar
• Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109–1119.e10 (2017). This study provides preliminary data from the treatment of patients with melanoma with combination therapy of T-VEC and pembrolizumab, which showed a 62% response rate and demonstrated T cell recruitment and PDL1 upregulation in the tumour microenvironment of treated melanomas.
  Article PubMed CAS Google Scholar
• Chesney, J. et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. https://doi.org/10.1200/JCO.2017.73.7379 (2017).
• Bommareddy, P. K., Peters, C., Saha, D., Rabkin, S. D. & Kaufman, H. L. Oncolytic herpes simplex viruses as a paradigm for the treatment of cancer. Annu. Rev. Cancer Biol. 2, 155–173 (2018).
  Article Google Scholar
• Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847–856 (2015).
  Article PubMed CAS Google Scholar
• Maleki Vareki, S., Garrigos, C. & Duran, I. Biomarkers of response to PD-1/PD-L1 inhibition. Crit. Rev. Oncol. Hematol. 116, 116–124 (2017).
  Article PubMed Google Scholar
• Lu, Z., Zhang, C., Sheng, J., Shen, J. & Liu, B. T cell receptor beta-chain repertoire analysis reveals the association between neoantigens and tumour-infiltrating lymphocytes in multifocal papillary thyroid carcinoma. Int. J. Cancer 141, 377–382 (2017).
  Article PubMed CAS Google Scholar
• Pasetto, A. et al. Tumor- and neoantigen-reactive T cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunol. Res. 4, 734–743 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Kloos, A., Woller, N., Gerardy-Schahn, R. & Kuhnel, F. Retargeted oncolytic viruses provoke tumor-directed T cell responses. Oncoimmunology 4, e1052933 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Dispenzieri, A. et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia 31, 2791–2798 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Samson, A. et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci. Transl Med. 10, eaam7577 (2018).
  Article PubMed Google Scholar
• Garcia-Carbonero, R. et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J. Immunother. Cancer 5, 71 (2017).
  Article PubMed PubMed Central Google Scholar
• Russell, S. J. et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin. Proc. 89, 926–933 (2014).
  Article PubMed PubMed Central Google Scholar
• Jiang, H. et al. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia 7, 48–56 (2005).
  Article PubMed PubMed Central CAS Google Scholar
• Kanai, R. et al. Effect of gamma34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J. Virol. 86, 4420–4431 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Reinboth, J. et al. Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates. Hum. Gene Ther. Methods 23, 285–296 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Wollmann, G., Rogulin, V., Simon, I., Rose, J. K. & van den Pol, A. N. Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J. Virol. 84, 1563–1573 (2010).
  Article PubMed CAS Google Scholar
• Dobrikova, E. Y. et al. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol. Ther. 16, 1865–1872 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Allen, C. et al. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin. Biol. Ther. 8, 213–220 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Zamarin, D. & Palese, P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol. 7, 347–367 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Nakaya, T. et al. Recombinant Newcastle disease virus as a vaccine vector. J. Virol. 75, 11868–11873 (2001).
  Article PubMed PubMed Central CAS Google Scholar